7-Oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasospastic diseases

Abstract: 7-Oxabicycloheptane imidazole prostaglandin analogs are provided which are useful in treating thrombotic and vasospastic disease and have the structural formula wherein m is 0, 1, 2, 3 or 4; n is 1, 2 or 3; and p is 1, 2 or 3; Z is -CH=CH-, -CH₂CH₂- or wherein Y is 0 or a single bond; R is CO₂H, CO₂lower alkyl, CO₂alkali metal, CONHSO₂R₂ (wherein R₂ is lower alkyl or aryl) or -CH₂-5-tetrazolyl; A is CHOH, C=O, (wherein R₃ is H or lower alkyl), or a single bond; R₁ is lower alkyl, aryl, cycloalkyl or H, R₁ can be H only when A is a single bond.

Description: The present invention provides 7-oxabicycloheptane imidazole prostaglandin analogs which are thromboxane A₂ (TXA₂) receptor antagonists or combined thromboxane A₂ receptor antagonists/thromboxane synthatase inhibitors useful, for example, in the treatment of thrombotic and/or vasospastic disease and have good duration of action. These compounds have the structural formula I and including all stereoisomers thereof, wherein m is 0, 1, 2, 3 or 4; n is 1, 2, or 3; and p is 1, 2 or 3; Z is (wherein Y is O or a singe bond); with the provisos that when m is 0, then Y is a single bond; R is CO₂H, CO₂lower alkyl, CO₂alkali metal CONHSO₂R₂ (wherein R₂ is lower alkyl or aryl) or -CH₂-5-tetrazolyl; A is CHOH, (wherein R₃ is H or lower alkyl), or a single bond; and R₁ is H, lower alkyl, aryl, or cycloalkyl; R₁ may be H only when A is a single bond. Thus, the compounds of the invention encompass the following types of compounds: US Patents US-A-4,526,901 and US-A-4,456,617 and European Patent Applications EP-A-374,952 (published 27.6.90) and EP-A-403,090 (published 19.12.90) disclose prostaglandin analogues with a different lower side chain and a Z group which is a C₂ aliphatic hydrocarbon group. European Patent Application EP-A-391,652 (published 10.10.90) discloses prostaglandin analogues in which Z may have the same value as that defined herein but wherein p is zero. The term "lower alkyl" or "alkyl" as employed herein refers to both straight and branched chain radicals of up to 12 carbons, preferably 1 to 8 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups including 1, 2 or 3 halo substituents, an aryl substituent, an alkyl-aryl substituent, a haloaryl substituent, a cycloalkyl substituent or an alkylcycloalkyl substituent. The term "cycloalkyl" refers to saturated cyclic hydrocarbon groups containing 3 to 12 carbons, preferably 3 to 8 carbons, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, any of which groups may be substituted with 1 or 2 halogens, 1 or 2 lower alkyl groups, 1 or 2 lower alkoxy groups and/or 1 or 2 hydroxy groups. The term "aryl" or "Ar" as employed herein refers to monocyclic or bicyclic aromatic groups containing from 6 to 10 carbons in the ring portion, such as phenyl, naphthyl. Aryl (or Ar), phenyl or naphthyl may include substituted aryl, substituted phenyl or substituted naphthyl, which may include 1 or 2 substituents on either the phenyl or naphthyl such as lower alkyl, trifluoromethyl, halogen (Cl, Br or F), lower alkoxy, aryloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, arylsulfinyl and/or arylsulfonyl. The term "aralkyl", "aryl-alkyl" or "aryl-lower alkyl" as used herein refers to lower alkyl groups as discussed above having an aryl substituent, such as benzyl. The term "lower alkoxy", "alkoxy" or "aralkoxy" refers to any of the above lower alkyl, alkyl or aralkyl groups linked to an oxygen atom. The term "halogen" or "halo" as used herein refers to chlorine, bromine, fluorine or iodine with chlorine being preferred. Preferred are those compounds of formula I wherein m is 2, n is 1, p is 1, R is CO₂H, A is CHOH, C=O, a single bond, and R₁ is cycloalkylalkyl, or H, and -A-R₁ is in the 4-position of the imidazole ring, Z is and Y is a single bond. The various compounds of the invention may be prepared as outlined below. The compounds of formula I of the invention may be prepared as follows. Compounds of the invention where A is CHOH are prepared starting with imidazole alcohol hydrochloride A which is neutralized by passing A through a column of anion exchange resin, hydroxy form, to form the free base B The free base B is then oxidized by treating a solution of B in an inert organic solvent such as dioxane, benzene or methylene chloride with manganese dioxide, or barium manganate under an inert atmosphere such as argon, to form the aldehyde C Aldehyde C is then made to undergo a Grignard reaction by teating C with a Grignard reagent of the structure D BrMg-R₁ (prepared by adding bromide E E Br-R₁ in an appropriate inert organic solvent such as tetrahydrofuran or diethyl ether to a stirred suspension of Mg turnings in an inert organic solvent such as tetrahydrofuran, or diethyl ether), employing a molar ratio of E : C of within the range of from about 1.5:1 to about 5:1, to form the alcohol F The alcohol F is treated with a protecting compound such as chlorodimethyl-t-butylsilane in the presence of an amine base such as triethylamine and an inert organic solvent such as dimethyl formamide or methylene chloride, employing conventional procedures, to form the protected compound G wherein Pro represents a protecting group. Examples of protecting compounds suitable for use herein in reacting with alcohol F include but are not limited to A solution of the protected alcohol G is formed in an inert solvent such as dimethylsulfoxide which is treated with a base such as sodium hydride (optionally in the presence of an inert carrier such as mineral oil) or lithium diisopropylamide (in tetrahydrofuran or hexanes). The resulting solution is treated with tosylate H (prepared as described in U.S. Patent US-A-4,663,336 where Z is other than interphenylene) employing a molar ratio of H : G of within the range of from about 1:1 to about 0.2:1 to form imidazole compound II Compound II is then deprotected using standard procedures, for example by treating a solution of II in an alcohol solvent, such as methanol, under an inert atmosphere, such as argon, with acetyl chloride to form the corresponding alcohol IE Compounds of the invention wherein A is C=O may be prepared by subjecting alcohol ester IE to allylic oxidation by treating a solution of IE in dioxane or benzene with an oxidizing agent such as activated manganese dioxide under an inert atmosphere such as argon, at a temperature within the range of from about 20°C to about 125°C, to form ester of the invention IF In a preferred embodiment, compounds of the invention wherein A is C=O may be prepared by treating tosylate H with imidazole J in the presence of a solvent such as dimethylformamide, THF or preferably dimethylsulfoxide, and base such as sodium hydride, potassium hydride, potassium tert-butoxide or 1,4-diazabicyclo[2.2.1]octane (DABCO), at a temperature within the range of from about 25 to about 90°C, employing a molar ratio of H : J of within the range of from about 0.95:1 to about 0.4:1, to form imidazole compound IF. Compounds of the invention wherein A is a single bond and R₁ is other than H may be prepared by heating a solution of imidazole K and tosylate H in anhydrous inert organic solvent such as anhydrous dimethylformamide, dimethyl sulfoxide or hexamethylphosphorictriamide (HMPA), at a temperature within the range of from about 20°C to about 125°C, employing a molar ratio of K : H of within the range of from about 1:1 to about 5:1, to form ester of the invention IG Compounds of the invention wherein A is a single bond and R₁ is H may be prepared by heating a solution of tosylate H and imidazole in an inert organic solvent such as dimethylformamide, dimethyl sulfoxide or HMPA, under an inert atmosphere such as argon, at a temperature within the range of from about 20°C to about 125°C, employing a molar ratio of H :imidazole of within the range of from about 1.1:1 to about 0.17:1, to form the ester of the invention IH Compounds of the invention wherein A is may be prepared by starting with imidazole carboxylic acid L which is treated first with a carboxyl activating agent such as 1,1'-carbonyl diimidazole in an inert organic solvent such as dimethylformamide and subsequently with an amine salt of the formula M in the presence of a tertiary amine base such as triethylamine to form the amide N Amide N is then condensed with tosylate H , employing a molar ratio of H : N of within the range of from about 1:1 to about 0.2:1, in the presence of base such as NaH, lithium diisopropyl amide or potassium t-butoxide, and an inert solvent such as dimethyl sulfoxide, dimethyl formamide or HMPA, at a temperature within the range of from about 20°C to about 125°C, to form compound IJ The esters IE, IF, IG, IH and IJ may be converted to the corresponding acids, that is IK by treating the esters with a base, such as lithium hydroxide, sodium hydroxide or potassium hydroxide to form the corresponding alkali metal salt, followed by neutralization with an acid, such as dilute hydrochloric acid or oxalic acid to form the acid compounds of the invention. Compounds of the invention wherein R is CONHSO₂R₂, that is IL are prepared by treating acid IK with a sulfonamide of the structure P in the presence of a coupling agent such as carbonyldiimidazole or ethyl -3(3-dimethylamino)propylcarbodiimide (WSC) and 4-dimethylaminopyridine, under an inert atmosphere such as argon, employing a molar ratio of P :IK of within the range of from about 0.8:1 to about 1.2:1, to form sulfonamide IL. Compounds of the invention wherein R is -CH₂-5-tetrazolyl, and Y is a single bond, that is IQ are prepared by subjecting esters IE, IF, IG, IH or IJ where Z is to reduction with a hydride reagent such as lithium borohydride or sodium borohydride to afford alcohol VIII which is converted to the bromide on treatment with triphenylphosphonium dibromide in an inert solvent such as toluene. The bromide is then converted to nitrile IX on treatment with an alkali metal cyanide in a polar solvent such as methanol/water. Compounds of the invention wherein R is -CH₂-5-tetrazolyl, and Y=O, that is IR are prepared by conversion of alcohol X to XI using the procedures set out herein for conversion of alcohol ester XIX to final products. Alcohol X may be prepared from alcohol XXII employing conventional homologation techniques as described in U.S. Patent US-A-4,663,336. XI is converted to nitrile XII by deprotection, for example with aqueous HCl when Pro is methoxymethyl followed by alkylation of the resulting phenol with halonitrile T in the T Hal-(CH₂) n -CN presence of a base such as sodium hydride or potassium carbonate. The nitriles are then subjected to a cycloaddition reaction by treating IX or XII with sodium azide in the presence of ammonium chloride, dimethylformamide and lithium chloride at temperatures from about 100°C to about 130°C to form IQ and IR respectively. Starting tosylate H where Y is a single bond and m is 1, 2, 3 or 4 are prepared starting with bromophenylalkyl alcohol U where m is 1, 2, 3 or 4 which is treated with a protecting compound such as t-butylchlorodiphenylsilane, in the presence of an amine base such as triethylamine and an inert solvent, employing conventional procedures, to form the protected bromophenylalkyl compound V wherein Pro represents a protecting group. Examples of protecting compounds suitable for use herein are as described hereinbefore. The protected compound V is then transmetallated by treatment with t-C₄H₉Li or n-C₄H₉Li in the presence of diethyl ether or tetrahydrofuran at reduced temperature of from about -100° to about 0°C or preferably is subjected to a Grignard reaction by treatment with magnesium in the presence of an inert organic solvent such as tetrahydrofuran (THF) or diethyl ether and then is condensed with (exo)octahydro-5,8-epoxy-1H-benzo-pyran-3-ol or (exo)octahydro-4,7-epoxyisobenzofuran-1-ol (prepared as described in U.S. Patent US-A-4,143,054) of the structure W employing a molar ratio of W : V of within the range of from about 1:2 to about 1:4, in the presence of an inert organic solvent such as THF at a reduced temperature of from about -78 to about 25°C, to form the condensed 7-oxabicycloheptane compound XV The condensed compound XV is then subjected to hydrogenolysis by treatment with hydrogen in the presence of a catalyst such as palladium hydroxide on charcoal in acetic acid or an inert organic solvent such as ethyl acetate, to form the alcohol XVI The alcohol function of alcohol XVI is protected by treatment, for example, with a solution of acetic anhydride, pyridine and 4-dimethylaminopyridine to form the protected alcohol XVII Alternatively, compound XVII can be protected by treatment with, for example, a solution of acetic anhydride and pyridine to form compound XVIII which is then subjected to hydrogenolysis as described above to provide compound XVII. The protected alcohol XVII wherein Pro is t-butyldimethylsilyl or dimethyl(1,1,2-trimethylpropyl)silyl is subjected to a Jones oxidation emplying procedures described hereinbefore to form crude acid which is deacetylated by reaction with aqueous hydroxide in the presence of inert organic solvent such as THF and then esterified, for example, by treatment with diazoalkane, such as diazomethane, or acidic alcohol such as methanolic HCl, to form the alcohol ester XIX In an alternative method for forming alcohol ester XIX, protected alcohol XVIII is subjected to a Jones oxidation and esterification for form ester XX which is then made to undergo hydrogenolysis and subsequent removal of the acetate protecting group by transesterification to afford alcohol ester XIX. Alcohol ester XIX is then tosylated by treatment of XIX with tosyl chloride in the presence of an organic base, such as pyridine or triethylamine, in the presence of an inert organic solvent such as methylene chloride, to form tosylate H . Starting tosylate H wherein and Y is O may be prepared as follows: Bromophenol A 1 is treated with a protecting compound such as chloro-t-butyldimethylsilane, benzyl bromide or bromomethyl methyl ether, preferably benzyl bromide or bromomethyl methyl ether for ortho-bromophenol, employing conventional procedures to form the protected bromophenyl compound B 1 wherein Pro represents a protecting group. Examples of protecting compounds suitable for use herein in reacting with bromophenol A¹ include those set out hereinbefore with respect to protection of alcohol U . Protected compound B 1 is then transmetallated (using a procedure similar to that set out above with respect to transmetallation of V using n-butyllithium in THF) and condensed with hemiacetal W to form the condensed 7-oxabicycloheptane compound XXI The condensed compound XXI is then subjected to hydrogenolysis by treatment with hydrogen in the presence of a catalyst such as palladium on charcoal in acetic acid, to form the alcohol XXII in the case where Pro is a silyl or methoxymethyl ether protecting group or to form XXV directly when Pro is benzyl. When Pro is a silyl protecting group, compound XXII is deprotected by treatment with, for example, a solution of acetonitrile and aqueous hydrofluoric acid to form the deprotected alcohol XXIII The alcohol XXIII is then alkylated by treating a solution of alcohol XXIII in tetrahydrofuran with a molar equivalent of sodium hydride or one to four equivalents of a carbonate base such as potassium carbonate. The resulting phenoxide solution is alkylated by treating with a haloalkanoic acid ester C 1 C 1 Hal-(CH₂) m -CO₂alkyl employing a molar ratio of C 1 :XXIII of from about 1:1 to about 3:1, in the presence of an inert organic solvent such as THF or dimethylformamide or dimethoxyethane, to form ester XXIV Alternatively, when the protecting group in XXII is methoxymethyl, the free hydroxyl is protected as a benzyl ether. The methoxymethyl protecting group is removed by treatment with aqueous acid. The resulting phenol is alkylated with ethyl bromoacetate as described above for the alkylation of XXIII. The benzyl protecting group is then removed by hydrogenolysis with palladium hydroxide and hydrogen to give XXIV. Alternatively, alcohol ester starting materials of formula XXIV may be prepared by following the procedure as described in U.S. Patent US-A-4,536,513. Starting tosylate H where where Y is a single bond and m is 0, that is benzoic acids or derivatives thereof of the structure IU may be prepared starting with bromobenzyl alcohol D 1 which is treated with a protecting compound such as t-butylchlorodiphenylsilane, in the presence of 4-dimethylaminopyridine and an amine base such as triethylamine and an inert solvent, such as methylene chloride, employing conventional procedures, to form the protected bromobenzyl compound E 1 wherein Pro represents a protecting group. Examples of protecting compounds suitable for use herein with the exclusion of benzyl bromide are as set out hereinbefore in reacting with bromophenalkyl alcohol U . The protected compound E 1 is then transmetallated by treatment with t-C₄H₉Li or n-C₄H₉Li in the presence of diethyl ether or tetrahydrofuran at reduced temperature of from about -100° to about 0°C (or is subjected to a Grignard reaction by treatment with magnesium in the presence of an inert organic solvent such as tetrahydrofuran (THF) or diethyl ether) and then is condensed with (exo)octahydro-5,8-epoxy-1H-benzopyran-3-ol or (exo)octahydro-4,7-epoxyisobenzofuran-1-ol of the structure W employing a molar ratio of W : E 1 of within the range of from about 1:2 to about 1:4, in the presence of an inert organic solvent such as THF at a reduced temperature of from about -78 to about 25°C, to form the condensed 7-oxabicycloheptane compound XXV Compound XXV is then protected by treatment with, for example, a solution of acetic anhydride and pyridine in the presence of 4-dimethylaminopyridine to form compound XXVI The protected alcohol XXVI is then deprotected using conventional procedures and the resulting alcohol subjected to a Jones oxidation employing procedures described hereinbefore to form crude acid. The crude acid is deacetylated by reaction with aqueous hydroxide in the presence of inert organic solvent such as THF and then esterified, for example, by treatment with diazoalkane, such as diazomethane, or acidic alcohol, to form the alcohol ester XXVII The alcohol ester is then subjected to hydrogenolysis as described above to provide alcohol ester compound XXVIII In a preferred method, compounds of the invention wherein m is 0, n is 1 and Y is a single bond, and R is in the ortho position, that is benzoic acids or derivatives thereof of the structure IW may be prepared starting with oxazoline (prepared as described by A.I. Meyers et al,in J. Org. Chem. 39 , 2787 (1974)) which is metallated by treatment with t-C₄H₉Li or n-C₄H₉Li in the presence of diethyl ether or tetrahydrofuran at reduced temperature of from about -100° to about 0°C and then is condensed with (exo)octahydro-4,7-epoxyisobenzofuran-1-ol (prepared as described in U.S. Patent US-A-4,143,054) of the structure F 1 employing a molar ratio of F 1 :oxazoline of within the range of from about 1:2 to about 1:4, in the presence of an inert organic solvent such as THF at a reduced temperature of from about -78 to about 0°C, to form the condensed 7-oxabicycloheptane compound XXIX Compound XXIX is then subjected to aqueous acidic hydrolysis by treatment with aqueous oxalic acid to form compound XXX XXX is then subjected to hydrogenolysis as described above and esterification to provide alcohol ester compound XXXI Compound XXXI may be used in place of alcohol XIX to form compounds of the invention IW where m is 0 and n is 1. The starting imidazole K in which A is attached at the 4 or 5 position of the imidazole ring may be prepared starting with acid G 1 which is treated with oxalyl chloride to form the corresponding acid chloride H 1 Acid chloride H 1 is treated with cyanotrimethyl silane under an inert atmosphere such as argon, at a temperature within the range of from about 20°C to about 150°C, to form the nitrile J 1 Nitrile J 1 is made to undergo reductive acylation by treating J 1 with a suspension of activated zinc dust in acetic anhydride and acetic acid, under an inert atmosphere such as argon, at a temperature within the range of from about 0°C to about 75°C, to form K 1 which is hydrolyzed by treating K 1 with hydrochloric acid under an inert atmosphere such as argon to form the amine hydrochloride L 1 Compound L 1 is then cyclized by reacting L 1 with an aqueous solution of KSCN, at a temperature within the range of from about 20°C to about 100°C, employing a molar ratio of L 1 :KSCN of within the range of from about 1:1 to about 0.25:1, to form imidazole thiol M 1 M 1 is subjected to reductive desulfurization by treating M 1 with a suspension of Raney nickel or other reducing agent in the presence of an inert organic solvent such as methanol or ethanol, under an inert atmosphere such as argon, at a temperature within the range of from about 20°C to about 90°C to form the starting imidazole K . The starting imidazole K in which R₁ is attached at the 2-position of the ring can be prepared by tretment of protected imidazole N 1 with a strong base, for example, n-butyllithium, in an inert solvent such as THF to form the anion which is condensed with an O 1 Hal-R₁ alkylating agent O 1 where Hal is a bromide, iodide or alkylsulfonate to form imidazole P 1 which is deprotected under standard conditions The compounds of this invention have four centers of asymmetry as indicated by the asterisks in formula I. However, it will be apparent that each of the formulae set out above which do not include asterisks still represent all of the possible stereoisomers thereof. All of the various stereoisomeric forms are within the scope of the invention. The various stereoisomeric forms of the compounds of the invention, namely, cis-exo, cis-endo and all trans forms and stereoisomeric pairs may be prepared by employing starting materials and following the procedures as outlined in U.S. Patent No. 4,143,054. Examples of such stereoisomers are set out below. The nucleus in each of the compounds of the invention is depicted as for matter of convenience; it will also be appreciated that the nucleus in the compounds of the invention may be depicted as The compounds of this invention are thromboxane receptor antagonists and as such are useful as inhibitors of thromboxane receptor mediated actions, and are also thromboxane synthetase inhibitors. The term "thromboxane receptor antagonist" includes compounds which are so-called thromboxane A₂ receptor antagonists, thromboxane A₂ antagonists, thromboxane A₂/prostaglandin endoperoxide antagonists, TP-receptor antagonists, or thromboxane antagonists. The compounds of this invention are useful as inhibitors of platelet function, i.e., for the prevention and treatment of thrombotic vascular occlusive disorders, whether complete or partial, for example, arterial thrombosis, including that of the coronary, cerebral, ophthalmic, hepatic, mesenteric, renal, peripheral arteries or vascular or organ grafts, unstable angina, transient ischemic attacks, or intermittent claudication. They may be useful to prevent thrombosis following vascular injury produced in the course of diagnostic or therapeutic procedures such as endarterectomy or angiography. The compounds may be useful in the treatment or prevention of disorders characterized by platelet consumption and/or activation, including, platelet activation, dysfunction, and/or loss during extracorporeal circulation, the use of radiographic contrast agents, thrombotic thrombocytopenia purpura, disseminated intravascular coagulation, purpura fulminans, hemolytic transfusion reaction, hemolytic uremic syndrome, systemic lupus, cyclosporine-induced renal toxicity, pulmonary hypertension, side effects from dialysis, or abdominal aortic aneurism repair. The compounds may be used in the treatment of venous thrombosis or embolism, including pulmonary embolism, deep venous thrombosis, hepatic vein thrombosis, and renal vein thrombosis. The compounds of this invention are useful as inhibitors of arterial or venous vasoconstriction. Accordingly, they may be useful to prevent vasoconstriction associated with unstable angina, chronic stable angina, and variant, or Prinzmetal's angina, Raynaud's syndrome, migraine headache, vasospasm of the coronary, cerebral, ophthalmic, hepatic, mesenteric, renal, peripheral arteries or vascular grafts, vascular injury such as that associated with surgery or trauma. Hypertension of pregnancy, the hepato-renal syndrome, and pulmonary hypertension are additional examples of vasoconstrictive disorders treatable by the compounds of this invention. The compounds of this invention are useful as inhibitors of bronchoconstriction, i.e., airway hyperresponsiveness, allergic bronchospasm, asthma, and bronchoconstrictive responses to environmental, infectious, noxious or mechanical stimuli. The compounds of this invention are useful as inhibitors of ischemic and reperfusion injury to various tissues, including, myocardium, skin, brain, bowel, or kidney, alone or in combination with other agents intended to restore blood flow. For example, these compounds may be useful for improving postischemic myocardial function and decreasing myocardial infarct size. Ischemia caused by reduced blood flow during diagnostic or therapeutic procedures may benefit by treatment with these compounds, for example, they reduce the myocardial stunning observed after bypass surgery. In addition, they may be useful for reducing the tissue injury caused by a stroke. The compounds of this invention may be useful in the prevention or treatment of other conditions including burns, diabetic retinopathy, tumor metastasis, and tardive dyskinesia. The compounds may be useful in potentiating diuretic-induced diuresis. In addition, the thromboxane receptor antagonists of the invention may be used with a thrombolytic agent such as t-PA, streptokinase, urokinase, prourokinase or anisoylated plasminogenstreptokinase activator complex (APSAC) within 6 hours of a myocardial infarction. In such case, the thrombolytic agent may be used in amounts conventionally employed, for example, as disclosed in the Physicians' Desk Reference for reducing post-ischemic myocardial injury. The compounds of the invention can be administered orally or parenterally to various mammalian species known to be subject to such maladies, e.g., humans, cats, dogs and the like in an effective amount within the dosage range of about 0.1 to about 100 mg/kg, preferably about 0.1 to about 50 mg/kg and especially about 2 to 25 mg/kg (or from about 5 to about 2500 mg, preferably from about 10 to about 2000 mg) on a regimen in single or 2 to 4 divided daily doses. The active substance can be utilized in a composition such as tablet, capsule, solution or suspension containing about 5 to about 500 mg per unit of dosage of a compound or mixture of compounds of formula I or in topical form for wound healing (0.01 to 5% by weight compound of formula I, 1 to 5 treatments per day). They may be compounded in conventional matter with a physiologically acceptable vehicle or carrier, excipient, binder, preservative, stabilizer, flavor, etc., or with a topical carrier such as Plastibase (mineral oil gelled with polyethylene) as called for by accepted pharmaceutical practice. Also as indicated in the discussion above, certain members additionally serve as intermediates for other members of the group. The compounds of the invention may also be administered topically to treat peripheral vascular diseases and as such may be formulated as a cream or ointment. The following Examples represent preferred embodiments of the present invention. Unless otherwise indicated, all tempertures are expressed in degrees Centigrade. Preparation I A. 1H-Imidazole-4-methanol The free base of 4-(hydroxymethyl) imidazole was prepared by passing 10.00 g of the hydrochloride (74.31 mmol) through a column of 187 mL of analytical grade anion exchange resin (Bio-Rad AG 1-X8, 100-200 mesh, hydroxide form, 1.2 meg/mL of resin bed). Elution with water was carried out until the eluent was no longer basic and no more of the free base was visible by TLC (silica, 90/10 CH₂Cl₂/CH₃OH). Eluent volume was ca. 650 mL. Water was removed in vacuo and azeotroped with toluene to yield 7.21 g of a white crystalline solid: ¹H NMR (CDCl₃/CD₃OD): δ 7.53, s (1H); 7.35, s (1H); 6.93, s (2H); 3.76, br s. B. 1H-Imidazole-4-carboxaldehyde A solution of Part A imidazole (7.21 g, 74.3 mmol) in 360 mL of dioxane with 86.9 g of activated MnO₂ (220.5 mmol) was refluxed under argon for 40 minutes. After cooling to room temperature the suspension was filtered through a pad of Celite and rinsed with several portions of hot dioxane (55°C); total rinse volume was 300 mL. Dioxane was removed in vacuo to yield 2.68 g of a white solid. The filter cake was rinsed with 300 mL each of boiling dioxane. Evaporation of the combined filtrates yielded an off-white solid which was combined with the above solid. The crude product was suspended in 50 mL of ethyl acetate, collected by filtration, rinsed with 25 mL of ethyl acetate then diethyl ether. Yield: 5.81 g of a white solid: mp 169-170°C dec.; ¹H NMR (CDCl₃/CD₃OD): δ 9.80, s (1H); 7.81, s (1H); 7.79 s (1H); 3.75, br s (1H). C. (3-Bromopropyl)cyclohexane Title compound was prepared as described in Kamm, O; Marvel, C.S. in Organic Synthesis 1921, 1 , 1-13, procedure G; ¹H NMR: δ 3.38, t, J=7Hz (2H); 0.83-1.91, m (15H). ¹³C NMR: δ 37.0, 35.9, 34.2, 33.2, 30.4, 26.6, 26.3. D. α-(3-Cyclohexylpropyl)-1H-imidazole-4-methanol To a stirred suspension of Mg turnings (4.40 g, 181.1 mmol) in 117 mL of tetrahydrofuran (THF) (room temperature, under argon) was added a few drops of a solution of 30.96 g (150.9 mmol) of Part C bromide in 25 mL of THF. Initiation was verified by the addition of a crystal of I₂ which immediately decolorized. The remaining solution of Part C bromide was then added dropwise so as to maintain a gentle reflux. After completion of the addition, stirring was continued for 45 minutes. Compound Part C bromide was completely consumed by TLC (silica, 75/25 hexanes/ethyl acetate two times, PMA). Part B compound (5.80 g, 60.4 mmol) was added in several increments and did not dissolve well. Reflux was initiated for 1 minute after which time most of Part B compound dissolved and the reaction proceeded vigorously without external heat application for 90 minutes. Reflux was subsequently carried out for 20 minutes. Complete consumption of Part B compound was indicated by TLC. After cooling to room temperature, the reaction mixture was poured over 72 mL of 20% aqueous HCl solution (0°C) and stirred for 5 minutes. THF was removed in vacuo , 200 mL of water were added, two extractions with 40 mL each of CHCl₃ were performed, and the reaction mixture was brought to pH 8.0 with 2M aqueous NaOH solution. The crude product was extracted 3 times with ethyl acetate (450 mL total), dried over Na₂SO₄ and concentrated to yield 13.33 g of an off-white sticky solid (99%). Trituration from 200 mL of diethyl ether (2 crops) yielded 12.57 g of a white crystalline solid: mp decomp >88°C; ¹ NMR: δ 9.29, br s (2H); 7.71 br s (1H); 6.85, br s (1H); 4.71, br s (1H); 1.78, br s (2H); 1.66, br s and 1.62, br s (5H); 1.41-1.15, m (8H); 0.83, m (2H). ¹³C NMR: δ 139.66, 134.68, 115.76, 66.49, 37.55, 37.62, 37.03, 33.34, 26.66, 26.35, 23.09. Preparation II A. 1H-Imidazole-4-carboxylic acid Compound A was prepared according to the method of Cohen, David, & Kirk (J. Het . Chem ., 19 , 253 (1982)). B. 4-Cyclohexylbutylamine hydrochloride To a stirred solution of 4-phenylbutylamine (10.6 g, 71.1 mmol, Aldrich) in 100 mL of glacial acetic acid under argon was added 87% PtO₂ (1.06 g, 10% weight based on 4-phenylbutylamine). The reaction mixture was hydrogenated at 54 psi at room temperature for 4 hours. The catalyst was removed by filtration through a 2" pad of Celite, and the filtrate was concentrated in vacuo . The residue was diluted with 200 mL of diethyl ether, 100 mL of CH₃OH and 8 mL of concentrated HCl. This mixture was concentrated in vacuo and triturated in diethyl ether to give 13.1 g (97%) of desired amine·HCl. C. N-(4-Cyclohexylbutyl) 1H-imidazol-4-carboxamide A suspension of 0.30 g of Part A acid (2.68 mmol) in 3.0 mL of dimethylformamide (DMF) (room temperature, argon) was treated with 0.52 g (3.21 mmol) of 1,1'-carbonyldiimidazole. Stirring was continued overnight. Triethylamine (0.45 mL, 3.21 mmol) was added followed by Part B amine (0.62 g, 3.21 mmol). Stirring was continued for 6 hours. The DMF was removed in vacuo (vacuum pump, dry ice-cooled receiver flask). Ethyl acetate and 30 mL of 0.1M HCl were added. The ethyl acetate layer was washed with 0.1M HCl (3 times, 5 mL each), saturated aqueous K₂CO₃ solution (3 times, 5 mL each), brine, dried over Na₂SO₄ and concentrated to yield 0.67 g of a yellow solid. Trituration from 10 mL of hexanes (1 crop) yielded 0.63 g of title compound in the form of an off-white solid. Example 1 [1S-(1α,2α,3α,4α)]-2-[[3-[[4-[[(Cyclohexylbutyl)amino]carbonyl]-1H-imidazol-1-yl]methyl]-7-oxabicyclo[2.2.2]hept-2-yl]methyl]benzenepropanoic acid, methyl ester A. 3-(2-Bromophenyl)-2-propenoic acid, methyl ester To a stirred suspension of 46.8 g (140 mmol, Aldrich) of methyl(triphenylphosphoranylidene)-acetate in 250 mL of dry tetrahydrofuran (THF) (distilled from potassium/benzophenone) at room temperature was added dropwise 25.0 g (135 mmol, Aldrich) of 2-bromobenzaldehyde, over 30 minutes. The reaction was mildly exothermic and became homogeneous. The resulting solution was stirred for 18 hours then concentrated in vacuo to give an oily solid. This material was slurried with 250 mL hexane and then filtered to remove solid triphenylphosphine oxide. The filtrate was concentrated in vacuo and the resulting oil was passed through a pad of silica gel (Merck silica, 9.5 x 2.0 cm, 1:4 ethyl acetate/petroleum ether elution). The eluant was concentrated in vacuo to give an oil. The crude oil was purified by bulb-to-bulb distillation (125-135°, ∼0.5 mm) to afford 32.0 g (133 mmol, 98%) of title acrylate as a pale yellow liquid. B. 2-Bromobenzenepropanoic acid, methyl ester A mixture of 14.0 g (58.1 mmol) of Part A acrylate and 750 mg of 5% rhodium on alumina catalyst (MCB) in 150 mL of methanol (Burdick and Jackson) was stirred under an atmosphere of hydrogen (balloon) for 3 hours (until the starting material was consumed by TLC). The reaction mixture was passed through a 4 µM polycarbonate membrane and the filtrate was concentrated in vacuo to give an orange oil. The oil was dissolved in 100 mL of diethyl ether then washed with 50 mL of saturated sodium bicarbonate solution, 50 ml of brine, dried (magnesium sulfate) and concentrated in vacuo to afford 13.7 g (56.4 mmol, 97%) of title compound as a pale yellow liquid. C. 2-Bromobenzenepropanol To a solution of 13.6 g (56.0 mmol) of Part B compound in 75 mL of toluene (Burdick and Jackson, sieve-dried) cooled to -78° was added 118 mL (1.0 M in toluene, 118 mmol, Aldrich) of diisobutylaluminum hydride solution. The reaction was stirred at -78° for 2 hours then warmed to 0° for 2 hours. The resulting solution was quenched by very slow addition of 10 mL of 6 N HCl then more rapid addition of 100 mL of 6 N HCl. The reaction was stirred for an additional 10 minutes, then added to 50 mL of diethyl ether and the organic layer was separated. The organic layer was washed with two-100 mL portions of 1 N HCl, 100 mL of brine, dried (magnesium sulfate) and concentrated in vacuo to afford 12.0 g (55.8 mmol, 100%) of title compound as a colorless oil. D. 1-Bromo-2-[3-[[Dimethyl(1,1,2-trimethylpropyl)silyl]oxy]propyl]benzene To a solution of 29.0 g (135 mmol) of crude Part C alcohol and 24.1 g (135 mmol, Petrarch) of thexyldimethylchlorosilane in 200 mL of dry methylene chloride (distilled from phosphorous pentoxide) was added at room temperature 20 mL (143 mmol, distilled from calcium hydride) of triethylamine then 200 mg (1.64 mmol, Aldrich) of 4-dimethylaminopyridine. The reaction mixture was stirred at room temperature for 18 hours. The resulting slurry was diluted with 100 mL of hexane, cooled to 0° with stirring for 15 minutes then filtered to remove solid triethylamine hydrochloride. The filtrate was concentrated in vacuo to give an oil. The crude oil was purified by flash chromatography (Merck silica, 15 x 10 cm, 1:9 ethyl acetate (EtOAc)/petroleum ether) to afford 45.5 g (127 mmol, 94%) of title compound as a colorless liquid. E. [1S-(1α,2α,3α,4α)]-[2-[3-[[Dimethyl(1,1,2-trimethylpropyl)silyl]oxy]propyl]phenyl]-7-oxabicyclo[2.2.1]heptane-2,3-dimethanol To a solution of 5.00 g (14.0 mmol) of Part D compound in 30 mL of dry diethyl ether (distilled from ketyl) cooled to -100° was added dropwise 15 mL (1.7M in pentane, 25 mmol, Aldrich) of t-butyllithium solution over 15 minutes. The reaction mixture was stirred at -100° for 15 minutes then at 0° for 15 minutes. The resulting pale yellow anion solution was recooled to -78° then 30 mL of dry THF (distilled from ketyl) was introduced followed by the rapid addition of a solution of 875 mg (5.61 mmol) of [3aR-(3aα,4β,7β,7aα)]-octahydro-4,7-epoxyisobenzofuran-1-ol in 10 mL of THF. The reaction mixture was warmed to 0°, stirred for 1 hour, quenched with 5 mL of water then partitioned between 100 mL of water and 25 mL of ethyl acetate. The organic layer was separated and the aqueous layer was extracted with an additional 25 mL of ethyl acetate. The organic extracts were combined, dried (magnesium sulfate) and concentrated in vacuo to give an oil. The crude oil was purified by flash chromatography (Merck silica, 12 x 5.0 cm, 1:4 ethyl acetate/petroleum ether then 4:1 ethyl acetate/petroleum ether) to afford 2.35 g (5.41 mmol, 97%) of title diasteromeric alcohols as a colorless oil. F. [1S-(1α,2α,3α,4α)]-2-[[2-[3-[[Dimethyl(1,1,2-trimethylpropyl)silyl]oxy]propyl]phenyl]methyl]-7-oxabicyclo[2.2.1]heptane-3-methanol A mixture of 1.90 g (4.38 mmol) of Part E diastereomeric alcohols and 1.9 g of 20% palladium hydroxide on carbon catalyst (moist, <50% water, Aldrich) in 60 mL of glacial acetic acid was stirred rapidly under an atmosphere of hydrogen (balloon) for 5 hours. The reaction mixture was filtered through a 4µM polycarbonate membrane and the filtrate was concentrated in vacuo (room temperature bath). The residue was partitioned between 50 mL of water and 50 mL of ethyl acetate. The organic layer was separated, washed with 50 mL of 1M aqueous sodium hydroxide solution, dried (magnesium sulfate) and concentrated in vacuo to give an oil. The crude material was purified by flash chromatography (Merck silica, 12 x 5.0 cm, 1:2 ethyl acetate/petroleum ether) to afford 1.03 g (2.39 mmol, 55%) of title compound as a colorless oil. In addition, 573 mg (1.37 mmol, 30%) of Part C starting material (as a single diastereomer) was recovered. G. [1S-(1α,2α,3α,4α)]-2-[[3-(Hydroxymethyl)-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, methyl ester A solution of 1.00 g (2.39 mmol) of Part F compound and 50 mg (0.41 mmol, Aldrich) of 4-dimethylaminopyridine in 6 mL of 1:1 dry pyridine/acetic anhydride was stirred at room temperature for 2 hours. The reaction mixture was concentrated in vacuo and the residue partitioned between 25 mL of ethyl acetate and 20 mL 1M aqueous HCl solution. The organic layer was separated, washed with 20 mL of 1M aqueous NaOH then 20 mL of brine, dried (magnesium sulfate) and concentrated in vacuo to afford the crude acetate as an oil. To a solution of the crude acetate in 15 mL of reagent acetone cooled to 0° was added rapidly 3.3 mL (2.6M in Cr⁺⁶, for preparation see Fieser & Fieser, "Reagents for Organic Synthesis," Vol. 1, p. 142) of Jones reagent. The reaction mixture was stirred for 2 hours, quenched by addition of 1 mL of isopropanol and stirred for an additional 30 minutes. The resulting green slurry was filtered through a pad of Celite. The filtrate was concentrated in vacuo and the residue partitioned between 25 mL of diethyl ether and 25 mL of water. The organic layer was separated and concentrated in vacuo to give the crude acetate-acid as an oil. A solution of the crude acetate-acid in 15 mL of 2:1 1M aqueous NaOH/THF was stirred at room temperature for 30 minutes. The reaction mixture was cooled in an ice-bath, quenched by addition of 15 mL of 1M aqueous HCl solution then extracted with two-25 mL portions of diethyl ether. The ether extracts were combined, washed with 25 mL of brine and concentrated in vacuo to give the crude alcohol-acid as an oil. A solution of the crude alcohol-acid in 10 mL of acidic methanol (prepared by addition of 0.5 mL of acetyl chloride to 10 mL of dry methanol at 0°) was stirred at 0° for 2 hours then concentrated in vacuo . The resulting oil was purified by flash chromatography (Merck silica, 15 x 3.0 cm, ethyl acetate) to afford 526 mg (1.76 mmol, 74% from Part F compound) of title compound as a colorless oil. In Parts H, I and J that follow, all chromatographies were performed with E. Merck Kieselgel 60 silica gel (240-400 mesh). H. [1S-(1α,2α,3α,4α)]-2-[[3-[[[(4-Methylphenyl)sulfonyl]oxy]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, methyl ester A solution of 0.33 g of Part G compound (1.08 mmol) in 14 mL of CH₂Cl₂ (room temperature, Ar) was treated with 0.41 g (2.15 mmol) of p-toluenesulfonyl chloride and pyridine (1.31 mL, 16.20 mmol). Stirring was continued overnight. TLC (silica, 50/50 hexanes/EtOAc) indicated unconsumed Part G compound. An additional portion of p-toluenesulfonyl chloride was introduced (0.21 g, 1.08 mmol) and the reaction was run over the weekend. TLC indicated complete consumption of Part G compound. Dichloromethane was evaportaed in vacuo and replaced with 15 mL of EtOAc. The EtOAc solution was washed 3 times with 5 mL each of 1M HCl, 4 times with 3 mL each of saturated aqueous K₂CO₃ solution, brine, dried over Na₂SO₄ and concentrated to an oil. Flash chromatography on 38 g of silica gel yielded 0.42 g of title compound in the form of a colorless viscous oil (84%). The product was eluted with 50/50 hexanes/EtOAc after complete elution of unreacted p-toluenesulfonyl chloride with 80/20 hexanes/EtOAc. ¹H NMR (270 MHz): δ 7.78, d (2H) and 7.34, d (2H), J=8.21 Hz; 7.16-7.08, m (4H); 4.36, d (1H) and 4.16, d (1H), J=4.69 Hz; 4.13-4.01, m (2H); 3.68, s (3H); 2.91, t (2H); 2.63-2.57, m (3H); 2.45, s (3H); 2.40-2.16, m (3H); 1.76-1.54, m (2H); 1.50-1.43, m (1H); 1.35-1.27, m (1H). ¹³C NMR (270 MHz): 173.04, 144.82, 138.48, 138.25, 132.95, 129.87, 129.47, 129.47, 128.92, 127.83, 126.53, 79.33, 78.84, 69.63, 56.76, 46.59, 46.25, 34.87, 30.21, 29.23, 27.47, 21.57. I. [1S-(1α,2α,3α,4α)]-2-[[3-[[4-[[(Cyclohexylbutyl)amino]carbonyl]-1H-imidazol-1-yl]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, methyl ester A solution of 0.30 g of Preparation II, Part C amide (1.20 mmol) in 3.0 mL of DMSO (room temperature, Ar) was treated with 0.048 g of NaH (1.20 mmol of a 60% mineral oil dispersion). Stirring was continued for 30 minutes. A solution of 0.35 g of Part H compound (0.76 mmol) in 4 mL of DMSO was added and the reaction was run @ 80°C (oil bath temperature) overnight. DMSO was removed in vacuo (vacuum pump, dry ice-cooled receiver flask). EtOAc (6 mL) and 1M HCl were added, the EtOAc layer was washed 3 times with 1M HCl (12 mL total), 3 times with saturated aqueous K₂CO₃ solution dried over Na₂SO₄ and evaporated in vacuo to yield 0.45 g of a tan taffy (>100%). Mineral oil was removed with hexanes (-78°C, 4 times, decanted, total 20 mL) without loss of product in the hexane decants by TLC. Flash chromatography on 42 g of silica gel (99/1 CH₂Cl₂/CH₃OH) yielded 0.27 g of title compound in the form of a colorless viscous oil. ¹H NMR (270 MHz): δ 7.62, 2 (1H); 7.48, s (1H); 7.18, m (4H); 4.26, d (1H) and 4.18, d (1H), J∼4.10 Hz; 4.01, m (2H); 3.67, s (3H); 3.39, q (2H); 2.98, t (2H); 2.75-2.58, m (4H); 2.39, m (2H); 1.66-1.17, m (19H); 0.94-0.78, br t (2H). ¹³C NMR (270 MHz): 172.72, 162.04, 138.16, 137.71, 136.48, 128.75, 128.67, 126.38, 120.89, 79.62, 78.37, 51.30, 47.71, 46.31, 46.12, 38.64, 37.19, 36.80, 24.51, 33.00, 30.00, 29.77, 29.29, 29.00, 27.20, 26.36, 26.03, 23.91. Example 2 [1S-(1α,2α,3α,4α)]-2-[[3-[[4-[[(Cyclohexylbutyl)amino]carbonyl]-1H-imidazol-1-yl]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid A solution of Example 1 compound (0.27 g 0.50 mmol) in 11.8 mL THF·2.4 mL H₂O was treated with 5.1 mL of a 1.0M aqueous LiOH solution. The cloudy, 2-layer reaction mixture was stirred vigorously for 4 hours. THF was removed in vacuo and the product was extracted 4 times with 5 mL each of chloroform. The combined chloroform layers were washed with brine, dried over Na₂SO₄ and concentrated to yield 0.24 g of a white solid. Flash chromatography on 17 g of silica gel with 99/1 EPAW* gave a residue which after EPAW removal in vacuo , was dissolved in a minimal amount of chloroform, filtered through a Gelman Acrodisc-CR filter disc (0.45 micron) and evaporated to yield a solid. Trituration from 4.0 mL of hexanes yielded 0.20 g of title compound in the form of an off-white solid. *EPAW = EtOAc/PAW; PAW=20/6/11 Pyridine/HOAc/H₂O ¹H NMR (270 MHz): δ 7.70, s (1H); 7.54, s (1H); 7.44, br s (4H); 4.29, d, J=3.52Hz (1H); 4.18, d, J=4.10Hz (1H); 4.02-3.98, m (2H); 3.38, q (2H); 3.00, t (2H); 2.74-261, m (4H); 2.41-2.36, m (2H); 1.69-1.50, m (9H); 1.40-1.17, m (10H); 0.88-0.83, m (2H). ¹³C NMR (270 MHz): δ 175.95, 162.44, 138.80, 138.02, 137.36, 137.04, 129.24, 126.85, 126.73, 126.16, 80.08, 78.79, 48.03, 46.88, 46.54, 39.28, 37.58, 37.15, 35.31, 33.38, 30.61, 29.92, 29.63, 29.09, 27.79, 26.72, 26.41, 24.28. Example 3 [1S-(1α,2α,3α,4α)]-2-[[3-[[4-(4-Cyclohexyl-1-oxobutyl)-1H-imidazol-1-yl]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, methyl ester A. [1S-[1α,2α,3α,4α]]-2-[[3-[[[(4-Methylphenyl)sulfinyl]oxy]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, methyl ester A solution of 0.33 g of Example 1, Part G alcohol (1.08 mmol) in 14 mL of CH₂Cl₂ (room temperature, argon) was treated with 0.41 g (2.15 mmol) of p-toluenesulfonyl chloride and pyridine (1.31 mL, 16.20 mmol). Stirring was continued overnight. TLC (silica, 50/50 hexanes/EtOAc) indicated unconsumed Example 1, Part G alcohol. An additional portion of p-toluenesulfonyl chloride was introduced (0.21 g, 1.08 mmol) and the reaction was run over the weekend. TLC indicated complete consumption of Example 1, Part G alcohol. Dichloromethane was evaporated in vacuo and replaced with 15 mL of EtOAc. The EtOAc solution was washed 3 times with 5 mL each of 1M HCl, 4 times with 3 mL each of saturated aqueous K₂CO₃ solution, brine, dried over Na₂SO₄ and concentrated to an oil. Flash chromatography on 38 g of silica gel yielded 0.42 g of title compound in the form of a colorless viscous oil (84%). The product was eluted with 50/50 hexanes/EtOAc after complete elution of unreacted p-toluenesulfonyl chloride with 80/20 hexanes/EtOAc. B. 4-(4-Cyclohexyl-1-oxobutyl)-1H-imidazole A suspension of 2.5 g of Preparation I Part D alcohol (11.24 mmol) in 55 mL of dioxane with 2.93 g, 33.77 mmol of MnO₂ was refluxed under Ar overnight. TLC (silica 90/10 CH₂Cl₂/CH₃OH) indicated the presence of unconsumed Example 1, Part D compound. An additional portion of MnO₂ was introduced (1.47 g) and reflux was continued for 5 hours. TLC indicated complete consumption of Preparation I, Part D compound. The reaction suspension was filtered through a pad of Celite and rinsed several times with a total of 100 mL of refluxing dioxane. Dioxane was removed in vacuo , the yellow oily residue was dissolved in 40 mL of ethyl acetate, washed 3 times with aqueous 2M trisodium citrate solution (20 mL total), dried over Na₂SO₄ and concentrated to yield 2.24 g of a light red-brown viscous oil (90%), of good purity by TLC. ¹H NMR and ¹³C NMR spectra of an earlier batch (J838-010-33) also indicated good crude product purity. Flash chromatography on 157 g of silica gel (97/3 CH₂Cl₂/CH₃OH then 97/3 CH₂Cl₂/CH₃OH) yielded 1.25 g of title compound in the form of an off-white solid (50%). The chromatography made little difference in product purity but greatly decreased the yield. ¹H NMR: δ 7.80, br s (1H); 7.75, s (1H); 2.82, br s (2H); 1.85-1.45, m (9H); 1.35-1.05 (6H); 1.90-1.80, m (2H). ¹³C NMR: δ 138.54, 39.42, 37.52, 37.12, 33.29, 26.67 26.35, 22.17. C. [1S-(1α,2α,3α,4α)]-2-[[3-[[4-(4-Cyclohexyl-1-oxobutyl)-1H-imidazol-1-yl]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, methyl ester and D. [1S-(1α,2α,3α,4α)]-2-[[3-[[5-(4-Cyclohexyl-1-oxobutyl)-1H-imidazol-1-yl]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, methyl ester A solution of 0.48 g of Part B compound (2.2 mmol) in 3.0 mL of DMSO (Ar) was cooled to 0°C. To the solidified mass was added NaH dispersion. Stirring at 0°C was continued for 20 minutes. Part A compound was added (0.40 g, 0.87 mmol) and the reaction was carried out at 72°C (oil bath temperature) overnight. DMSO was removed with a vacuum pump/dry ice-cooled receiver flask. Ethyl acetate and 1M HCl were added, the ethyl acetate layer was washed 3 times with 1M HCl, 3 times with saturated aqueous K₂CO₃ solution, brine, dried over Na₂SO₄ and concentrated to yield 0.76 g of a viscous brown oil. Flash chromatography on 52 g of silica gel with 99/1 CH₂Cl₂/CH₃OH yielded 0.36 g of a viscous yellow oil consisting of unseparated Part C and D compound. The product was re-chromatographed on 25 g of silica gel with 99/1 EPAW*. Yield: 0.26 g of Part C compound, a viscous yellow oil, 0.04 g of Part D compound and 0.08 g of a mixture of C and D compound. Compound C ¹H NMR: δ 7.65, s (1H); 7.57, S (1H); 7.19, br s (4H); 4.28, d, J=3.69 Hz (1H); 4.19, d, J=4.22 H (1H); 4.03-4.00, m (2H); 3.68, s (3H); 2.97, m (4H); 2.78-2.56, m (4H); 2.39, m (2H); 1.73-1.69, m (9H); 1.42-1.39, m (2H); 1.26-1.18, m (8H); 0.08, m (2H). Compound D ¹H NMR: δ 7.84, s (1H), 7.71, s (1H); 7.24-7.15 m (4H); 4.63, dd, J=12.66 Hz, J=3.70 Hz (1H); 4.23, d, J=4.22 Hz (1H); 4.17, d, J=4.22 Hz (1H); 4.05, dd, J=12.66 Hz, J=11.08 Hz (1H); 3.68 s (3H); 3.04, t (2H); 2.80, dd (partially obscured), J=4.22 Hz (1H); 2.78, t (2H); 2.67-2.63, m (3H); 2.44-2.37, m (2H); 1.73-1.63, m (9H); 1.39-1.10, m (11H); 0.95-0.80, m (2H). Example 4 [1S-(1α,2α,3α,4α)]-2-[[3-[[4-(4-Cyclohexyl-1-oxobutyl)-1H-imidazol-1-yl]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid A solution of 0.26 g of Example 3 compound (0.52 mmol) in 12 mL of THF (room temperature, Ar) was treated with 5.0 mL of 1.0M aqueous LiOH solution. Rapid stirring of the 2-phase reaction mixture was carried out for 3.5 hours. THF was removed in vacuo . Chloroform and 1M HCl were added (to pH 1.0), the aqueous layer was extracted 4 times with chloroform, the combined chloroform layers were washed with brine, dried over Na₂SO₄ and concentrated to yield 0.26 g of a solid. Flash chromatography on 17 g of silica gel with 99/1 EPAW* yielded 0.21 g of title compound in the form of a white solid. *EPAW=EtOAc/PAW PAW=20/6/11 pyridine/acetic acid/H₂O. ¹H NMR: δ 7.76, s (1H); 7.65, s (1H); 7.22-7.18, m (4H); 5.70-4.35, br s; 4.31, d (1H) and 4.21, d (1H), J=4.11 Hz; 4.11, dd, J=4.69 Hz, J=14.07 Hz (1H); 4.03, dd, J=13.00 Hz, J=14.07 Hz (1H); 2.99, t (2H); 2.90, t (2H); 2.74, dd, J=14.07 Hz, J=4.69 Hz (1H); 2.67-2.57, m (3H); 2.43-2.34, m (2H); 1.71-1.66, m (9H); 1.44-1.36, m (2H); 1.27-1.10, m (8H); 0.88-0.85, m (2H). ¹³C NMR: δ 196.33, 176.21, 141.82, 138.68, 138.14, 137.91, 129.30, 129.06, 126.82, 126.65, 123.16, 79.79, 78.70, 48.06, 46.91, 46.53, 39.13, 37.46, 37.03, 35.04, 33.23, 30.61, 29.51, 29.03, 27.56, 26.64, 26.32, 21.48.

Claims: A compound having the formula including all stereoisomers thereof, wherein m is 0, 1, 2, 3 or 4; n is 1, 2 or 3; p is 1, 2 or 3; Z is wherein Y is O or a single bond, with the proviso that when m is 0, then Y is a single bond; R is CO₂H, CO₂alkali metal, Co₂alkyl, CONHSO₂R₂ (wherein R₂ is alkyl or aryl) or -CH₂-5-tetrazolyl; A is CHOH, C=O, (wherein R₃ is H or alkyl), or a single bond; R₁ is alkyl, aryl, cycloalkyl or H with the proviso that R₁ can be H only when A is a single bond; wherein "alkyl" means straight and branched chain radicals of up to 12 carbons, as well as such groups including 1, 2 or 3 halo substituents, an aryl substituent, an alkyl-aryl substituent, a haloaryl substituent, a cycloalkyl substituent or an alkylcycloalkyl substituent; "cycloalkyl" means saturated cyclic hydrocarbon groups containing 3 to 12 carbons, any of which groups may be substituted with 1 or 2 halogens, 1 or 2 lower alkyl groups, 1 or 2 lower alkoxy groups and/or 1 or 2 hydroxy groups; "aryl" means optionally substituted monocyclic or bicyclic aromatic groups containing from 6 to 10 carbons in the ring portion; and "alkoxy" means a lower alkyl group (as just defined) linked to an oxygen atom. The compound as defined in claim 1 having the formula The compound as defined in Claim 2 where m is 2, n is 1 and p is 1. The compound as defined in Claim 1 having the formula The compound as defined in Claim 4 wherein m is 2, n is 1 and p is 1. The compound as defined in Claim 1 having the formula The compound as defined in Claim 6 wherein n is 1, m is 2 and p is 1. The compound as defined in Claim 1 having the formula The compound as defined in Claim 8 wherein n is 1, m is 2 and p is 1. The compound as defined in any preceding claim wherein R is CO₂H, CONHSO₂R₂ or -CH₂-5-tetrazolyl. The compound as defined in claim 10 wherein Y is a single bond. The compound as defined in Claim 1 having the name [1S-(1α,2α,3α,4α)]-2-[[3-[[4-[[(cyclohexylbutyl)amino]carbonyl]-1H-imidazol-1-yl]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid or its methyl ester. The compound as defined in Claim 1 having the name [1S-(1α,2α,3α,4α)]-2-[[3-[[4-(4-cyclohexyl-1-oxobutyl)-1H-imidazol-1-yl]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid or its methyl ester. A composition for inhibiting platelet aggregation and/or bronchoconstriction comprising an effective amount of a compound as defined in any preceding claim, and a pharmaceutically acceptable carrier therefor. A compound as defined in any one of Claims 1-14 for inhibiting platelet aggregation, inhibiting bronchoconstriction associated with asthma, improving post-ischemic myocardial dysfunction, treating toxemia during pregnancy, preventing or reducing venous thrombosis, preventing or reducing platelet loss during extracorporeal circulation, treating burn injuries and/or promoting wound healing by administration in systemic or topical form, or reducing post-ischemic myocardial injury within 6 hours of myocardial infarction. Use of a compound as defined in any one of Claims 1-14 for the manufacture of a medicament for inhibiting platelet aggregation. Use of a compound as defined in any one of Claims 1-14 for the manufacture of a medicament for inhibiting bronchoconstriction associated with asthma. Use of a compound as defined in any one of Claims 1-14 for the manufacture of a medicament for improving post-ischemic myocardial dysfunction. Use of a compound as defined in any one of Claims 1-14 for the manufacture of a medicament for treating toxemia during pregnancy. Use of a compound as defined in any one of Claims 1-14 for the manufacture of a medicament for preventing or reducing venous thrombosis. Use of a compound as defined in any one of Claims 1-14 for the manufacture of a medicament for preventing or reducing platelet loss during extracorporeal circulation. Use of a compound as defined in any one of Claims 1-14 for the manufacture of a medicament for treating burn injuries and/or promoting wound healing by administration in systemic or topical form. Use of a compound as defined in any one of Claims 1-14 for the manufacture of a medicament for reducing post-ischemic myocardial injury within 6 hours of myocardial infarction in a mammalian host to which or to whom a thrombolytic agent is also administered. The use as defined in Claim 23 wherein said thrombolytic is t-PA, streptokinase, urokinase, prourokinase or anisoylated plasminogen-streptokinase activator complex.

Inventors: HALL STEVEN E, STEIN PHILIP D, HALL, STEVEN E., STEIN, PHILIP D.
Applicants: SQUIBB & SONS INC, E.R. SQUIBB & SONS, INC.
Application year: 1991
Main classification: C07D493
IPC codes: A61P9, A61K31, C07D493, A61K38, A61P15, A61P13, A61P11, A61P43, A61P7